

Ontario Public Drug Programs

Drug Submission Status
Updated: March 20, 2015

Complete Streamlined Multiple-Source Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Natco Pharma (Canada) Inc.	Nat-Zolmitriptan	Zomig	zolmitriptan	2.5mg	FC tablet	02421534
Natco Pharma (Canada) Inc.	Nat-Rizatriptan ODT	Maxalt RPD	rizatriptan benzoate	5mg	OD tablet	02436604
Natco Pharma (Canada) Inc.	Nat-Rizatriptan ODT	Maxalt RPD	rizatriptan benzoate	10mg	OD tablet	02436612
Ranbaxy Pharmaceuticals Canada Inc.	Ran-Esomeprazole	Nexium	esomeprazole magnesium	20mg	DR tablet	02423979

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Ranbaxy Pharmaceuticals Canada Inc.	Ran-Esomeprazole	Nexium	esomeprazole magnesium	40mg	DR tablet	02423987